Application of prevention and treatment strategy taking TRPM2 as target spot in periodontitis
By constructing a TRPM2 gene knockout mouse model and using a TRPM2 inhibitor, we solved the problem of regulating oxidative stress response in periodontitis, reduced periodontal ligament cell damage, restored periodontal tissue function, and inhibited the development of periodontitis.
Patent Information
- Application Number
- CN202411350197.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-26
- Publication Date
- 2024-11-15
Smart Images

Figure CN118949041A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedical technology, and in particular to an application of a prevention and treatment strategy targeting TRPM2 in periodontitis. Background Art
[0002] Periodontitis is an inflammatory, destructive disease caused by bacterial infection that affects the periodontal supporting tissues, leading to periodontal pocket formation, gingival bleeding, attachment loss, and alveolar bone resorption. Periodontitis affects the periodontal health of approximately 538 million people worldwide, and has become a major problem that endangers human oral health and affects people's quality of life. At the same time, the onset of periodontitis is closely related to overall health status and may become a risk factor for many systemic diseases, such as cardiovascular disease, diabetes, nervous system diseases, respiratory diseases, and digestive system diseases, affecting the health of systemic tissues or organs outside the oral cavity. Therefore, there is an urgent need to develop effective strategies for the prevention and treatment of periodontitis.
[0003] The pathogenesis of periodontitis is complex, and oxidative stress has been considered to be one of the important pathological mechanisms of the occurrence and development of periodontitis. Oxidative stress refers to a stress state in which the body produces excessive reactive oxygen species (ROS) when it is exposed to various harmful stimuli, causing an imbalance in the oxidation and antioxidant systems, leading to damage to cell structure and function. Oxidative stress-mediated periodontal pathological changes mainly occur through two pathways: (1) causing cell dysfunction, apoptosis and necrosis; (2) activating inflammatory responses, releasing inflammatory mediators, and causing tissue damage. Therefore, oxidative stress plays a key role in periodontitis tissue destruction. However, the proteins that regulate this process and the molecular mechanisms of related signal transduction have not yet been clarified. Seeking new therapeutic targets based on the mechanism has become a research hotspot in this field.
[0004] The transient receptor potential M2 channel (TRPM2) is a non-selective cation channel located on the cell membrane surface and is considered a new type of oxidative stress receptor. Studies have confirmed that TRPM2, as a key gating channel, can mediate NLRP3 inflammasome activation in the process of crystal-induced cellular inflammation and dry eye diseases. However, the regulation of TRPM2 on the oxidative stress response in periodontitis is still unclear. Summary of the invention
[0005] In order to solve the defects and shortcomings in the above-mentioned prior art, the purpose of the present invention is to determine the effect of TRPM2 on the oxidative stress response of periodontitis and its regulatory mechanism. The TRPM2 gene can be used as a target for reducing oxidative stress damage of periodontal ligament cells in the treatment of periodontitis. The damage of periodontal ligament cells can be reduced by TRPM2 inhibitors, knocking out and / or knocking down the target TRPM2 gene, thereby effectively inhibiting the development of periodontitis.
[0006] In order to achieve the above object, the present invention adopts the following technical solutions:
[0007] In the present invention, by constructing TRPM2 gene knockout mice and conducting an experimental periodontitis model, it was found that TRPM2 gene knockout effectively alleviated periodontal tissue damage, which was manifested by reduced alveolar bone resorption, reduced periodontal tissue osteoclasts, restored alveolar bone osteogenic differentiation function, and reduced periodontal tissue oxidative stress levels.
[0008] Furthermore, by constructing an in vitro H2O2-induced oxidative stress injury model of human periodontal stem cells (hPDLSCs), the role of TRPM2-mediated mitochondrial dysfunction in the oxidative stress injury of periodontal ligament cells was double verified by using TRPM2 chemical inhibitor 2-Aminoethyl diphenylbonnate (2-APB) and gene knockout. The results showed that after intervention with TRPM2 chemical inhibitor and siTRPM2, the apoptosis level of hPDLSCs was reduced, the osteogenic differentiation function of hPDLSCs was restored, and the mitochondrial oxidative stress level was reduced.
[0009] This indicates that the TRPM2 gene can be used as a target in treatment to design and prepare drugs and / or biological agents that reduce oxidative stress damage to periodontal ligament cells in the treatment of periodontitis, so as to achieve the purpose of alleviating and / or treating oxidative stress damage to periodontal ligament cells.
[0010] For example, with TRPM2 as the target gene, double-stranded siRNA (small interfering RNA) that can interfere with TRPM2 expression is designed. After being synthesized by chemical methods, it is injected into the human body to silence the TRPM2 gene through RNA interference to alleviate or / and treat oxidative stress damage of periodontal ligament cells; TRPM2 mutants can also be designed and constructed, which enter cells after injection to compete for the substrate of the TRPM2 prototype, thereby inhibiting the function of TRPM2 and achieving the purpose of treatment; in addition, small molecule compound inhibitors or antibodies can be designed with TRPM2 as the target. By constructing a periodontal ligament cell targeted delivery system to deliver TRPM2 antibodies, small molecule inhibitors, etc. to periodontal ligament cells, an efficient and low-side effect treatment plan can be achieved, providing a new option for the treatment of periodontitis.
[0011] The TRPM2 gene sequence is a published gene sequence (NCBI Reference Sequence: NG_022913.2).
[0012] In view of the above functions of TRPM2,
[0013] In a first aspect, the present invention provides the use of TRPM2 as a drug target in screening products that reduce oxidative stress damage to periodontal ligament cells in the treatment of periodontitis.
[0014] Furthermore, the product comprises an inhibitor of TRPM2.
[0015] Furthermore, the TRPM2 inhibitor includes siRNA of the TRPM2 gene, RNA interference vector of the TRPM2 gene, antibody of TRPM2 or other inhibitors capable of inhibiting the expression of TRPM2.
[0016] Furthermore, the product includes a drug or a biological agent.
[0017] The second aspect of the present invention provides the use of a TRPM2 inhibitor in the preparation of a product for reducing oxidative stress damage to periodontal ligament cells in the treatment of periodontitis.
[0018] The third aspect of the present invention provides a targeted drug for reducing oxidative stress damage of periodontal ligament cells in the treatment of periodontitis, comprising an inhibitor of TRPM2.
[0019] Furthermore, it also comprises a pharmaceutically acceptable carrier or excipient, wherein the carrier is used for targeted delivery of the TRPM2 inhibitor to periodontal ligament cells.
[0020] Furthermore, the TRPM2 inhibitor includes siRNA of the TRPM2 gene, RNA interference vector of the TRPM2 gene, antibody of TRPM2 or other inhibitors capable of inhibiting the expression of TRPM2.
[0021] Compared with the prior art, the present invention has the following beneficial effects:
[0022] The present invention has discovered a new use of TRPM2. The damage to periodontal ligament cells can be reduced by using a TRPM2 inhibitor, knocking out and / or knocking down the target TRPM2 gene, thereby effectively inhibiting the development of periodontitis. Based on the research on the role and mechanism of action of TRPM2 in periodontitis, it provides a new therapeutic target and a new option for reducing oxidative stress damage to periodontal ligament cells in the treatment of periodontitis, and provides a target for developing products that reduce oxidative stress damage to periodontal ligament cells in the treatment of periodontitis. TRPM2 inhibitors can be used to prepare products that reduce oxidative stress damage to periodontal ligament cells in the treatment of periodontitis, and delivering TRPM2 inhibitors to periodontal ligament cells is a new option for the treatment of periodontitis. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] The present invention is further described in detail below with reference to the accompanying drawings and specific embodiments.
[0024] Figure 1 This is a diagram showing alveolar bone resorption in the experimental periodontitis model of TRPM2 gene knockout mice in the present invention;
[0025] Figure 2 It is the TRAP staining diagram in the present invention;
[0026] Figure 3 It is the ALP staining diagram in the present invention;
[0027] Figure 4 This is a test diagram of the immunofluorescence staining method for detecting the expression of 8-OHdG in the periodontal tissue of mice in the present invention;
[0028] Figure 5 This is a graph showing changes in proliferation activity and apoptosis of hPDLSCs after adding TRPM2 inhibitors and TRPM2-siRNA in the present invention;
[0029] Figure 6 This is a graph showing changes in the osteogenic differentiation ability of hPDLSCs after adding TRPM2 inhibitors and TRPM2-siRNA in the present invention;
[0030] Figure 7 This is a diagram showing the changes in mitochondrial function of hPDLSCs after adding TRPM2 inhibitors and TRPM2-siRNA in the present invention. DETAILED DESCRIPTION
[0031] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0032] 1. Experimental study on alveolar bone resorption in mice with periodontitis
[0033] 1.1 Experimental Grouping
[0034] Twenty-four 6-8 week old TRPM2 gene-deficient C57BL / 6 transgenic male mice (KO) were randomly divided into two groups with 12 mice in each group, and 24 wild-type C57BL / 6 male mice (WT) from the same litter were randomly divided into two groups with 12 mice in each group. The details are as follows:
[0035] (1) WT: wild-type control group in the same cage.
[0036] (2) WT+ligation: wild-type mice in the same cage + ligation-induced periodontitis group.
[0037] (3) TRPM2- / -: transgenic mouse group lacking the TRPM2 gene.
[0038] (4) TRPM2- / -+ligation: transgenic mice with TRPM2 gene deletion + ligation-induced periodontitis group.
[0039] 1.2 Construction of experimental periodontitis model
[0040] (1) Anesthesia: Prepare 2% pentobarbital, weigh the mouse, and inject it intraperitoneally at a dose of 0.2 ml / 10 g to anesthetize the mouse;
[0041] (2) Place the mouse in a mouse holder, suspend the lower jaw, open the oral cavity, and expose the maxillary posterior teeth;
[0042] (3) Under headlight illumination, use microsurgical forceps to wrap 5-0 mousse wire around the mesiodistal part of the maxillary second molar of the mouse and tie a knot on the palatal side of the second molar;
[0043] (4) After the end, place the mouse on an electric blanket until it wakes up from anesthesia;
[0044] (5) The periodontitis modeling lasted for 14 days from the start of ligation to puncture. During this period, the retention of the ligature was checked regularly. If it was loose, it was re-ligated immediately.
[0045] 1.3 Collection of mouse alveolar bone samples
[0046] (1) In accordance with the principles of experimental animal welfare and ethics, all mice were euthanized by overdose of anesthesia;
[0047] (2) After killing, the maxilla of the mouse was quickly obtained, separated along the mid-palatal suture, most of the muscle tissue was removed, and placed in marked embedding boxes. The left maxilla was used for subsequent detection of the degree of alveolar bone absorption in the mouse, and the right maxilla was used for subsequent paraffin sectioning;
[0048] (3) Place the embedding box in at least 10 volumes of 4% paraformaldehyde and fix at 4°C for 24 h.
[0049] 1.4 Detection of alveolar bone resorption in mice
[0050] (1) The left maxillary bone fixed with paraformaldehyde was treated with running water overnight;
[0051] (2) The soft tissue around the alveolar bone was carefully peeled off, and the alveolar bone loss (ABL) of the maxillary second molars of each group of mice was examined using a stereomicroscope. The distance from the mesial and distal cementoenamel junction to the alveolar bone crest of each specimen was measured. This was repeated three times, and the average of the measured values for each tooth was taken as the ABL value of the tooth.
[0052] (3) The left maxillary tissue that had been photographed under a stereomicroscope was stored in 75% ethanol and wrapped with sealing film to prevent the tissue from completely drying out. After Micro-CT (microcomputed tomography) scanning, the scanned images were three-dimensionally reconstructed using the Micro-Reconstruct system, and the surface reconstruction was performed using the Micro-View image analysis system to obtain a 2D image of the coronal plane. The 3D image was reconstructed using CTvox, and quantitative data such as bone mineral density (BMD) and bone volume fraction (BV / TV) were obtained by CTAn analysis.
[0053] 2. Experiment on detecting periodontal osteoclasts in periodontitis mice using tartrate resistant acid phosphatase (TRAP)
[0054] 2.1 Preparation of maxillary paraffin sections
[0055] (1) The right maxillary bone was fixed with paraformaldehyde and then treated in running water overnight;
[0056] (2) Decalcification: The right maxillary tissue was placed in a 10% EDTA decalcification solution with a pH of 7.5 and placed on a 4°C horizontal shaker. The decalcification solution was changed every 2 days. When the needle could penetrate the tissue without resistance, decalcification was completed.
[0057] (3) After decalcification, the tissue was washed with PBS three times, 1 h each time, to wash away the residual decalcification solution;
[0058] (4) For the detailed procedures of dehydration, transparency and wax dipping, please refer to Part 1;
[0059] (5) Embedding: Use forceps to clamp the first molar crown-root direction, align the palatal side of the tissue with the bottom of the embedding box, and ensure that the palatal cusp cannot be seen from the buccal side. Place it on a freezing table to cool until the paraffin solidifies.
[0060] (6) Sectioning: Use a LEICA manual wheel slicer to slice tissue, with each slice set to 4 μM thickness. Separate each slice in room temperature water, pick up the slice with an adhesive glass slide, and place the wax slide in a 45°C slide bath for about 15 min. When the tissue surface is flat and has no obvious wrinkles, use an adhesive glass slide to pick up the slice, make the long axis of the tissue parallel to the long axis of the slide, mark it, and place the slide in a 60°C slide bath for about 120 min to melt the wax and eliminate the water droplets on the surface.
[0061] (7) Store at 4°C for subsequent staining.
[0062] 2.2 TRAP staining of paraffin sections
[0063] (1) Slice baking: Place tissue slices in a 60°C slice baking bath for 1 h;
[0064] (2) Dewaxing and hydration: The prepared sections were placed in xylene I, xylene II, and anhydrous ethanol for 5 min each, then placed in 95% ethanol, 85% ethanol, and 75% ethanol for 3 min each, and finally placed in ddH2O for 2 min;
[0065] (3) The sections were fixed with 4% paraformaldehyde for 30 seconds and then rinsed with PBS three times, 3 minutes each time;
[0066] (4) Prepare TRAP staining solution as shown in Table 1, add 50 μl to each tissue, incubate in a 37°C wet box in the dark for 2 h, and terminate staining with ddH2O;
[0067] Table 1
[0068] TRAP staining solution Volume (μL) Total TRAP Fluid 1000 Mixl -- FastGarnetGBSBase 10 SodiuMNitrate 10 Mix2 -- MilliQwater 900 Mix1 20 Acetatesolution 50 NaphtholA5-BI 10
[0069] (5) Counterstaining: add 50 μl of methylchloro-pyronine to each tissue, terminate the color development with ddH2O after 25 seconds, and rinse with running water for 5 minutes;
[0070] (6) After the slices were naturally air-dried, they were sealed with neutral gum and the images were saved by a microscope and statistical analysis was performed.
[0071] 3. Experiment on the detection of osteogenic differentiation of periodontal tissue cells by alkaline phosphatase (ALP) staining
[0072] 3.1 Preparation of maxillary paraffin sections is the same as 2.1.
[0073] 3.2 ALP staining
[0074] (1) The specific steps of baking, dewaxing and hydration are the same as 2.2(1)(2);
[0075] (3) Add 50 μl of hydrogen peroxide to the tissue, place the tissue in a dark environment, and incubate at room temperature for 12 min.
[0076] Rinse the tissue twice with PBS, 2 min each time;
[0077] (4) Add 50 μl of blocking solution to each tissue, place the sections in a humidified chamber, and incubate at 37°C for 20 min;
[0078] (5) Prepare ALP staining working solution according to Table 2, add 50 μl to each tissue, and place the tissue in a light-proof humidified box.
[0079] Incubate at 37°C for 30 min, and terminate the reaction with ddH2O;
[0080] Table 2
[0081] ALP staining working solution 3.03ml Alkaline phosphatase colorimetric buffer 3ml BCIP solution (300x) 10μl NBT solution (150x) 20μl
[0082] (6) Counterstaining: Add 50 μl of neutral red to the tissue to counterstain the cell nucleus. After 2 minutes, add ddH2O to stop staining.
[0083] Dye, rinse in running water for 5 minutes;
[0084] (7) After the slices are naturally air-dried, they are sealed with neutral gum and scanned to save the images for statistical analysis.
[0085] IV. Immunofluorescence staining to detect periodontal oxidative stress levels
[0086] 4.1 Preparation of maxillary paraffin sections is the same as 2.1;
[0087] 4.2 Immunofluorescence staining
[0088] (1) The specific steps of baking, dewaxing and hydration are the same as 2.2(1)(2);
[0089] (2) Use an immunohistochemistry pen to draw a circle around the tissue, being careful not to touch the tissue. Add 50 μl of trypsin to each tissue and rinse with PBS twice, 2 min each time.
[0090] (3) Add 50 μl of 3% hydrogen peroxide to each tissue, place the tissue in a dark environment, incubate at room temperature for 12 min, and then rinse twice with PBS, 2 min each time;
[0091] (4) Add 5% BSA to each tissue for antigen blocking, place the tissue in a light-proof humidified box, and incubate at 37°C for 1 h;
[0092] (5) Shake off the blocking solution, add 50 μl of a mixture of antibody TOM20 (1:300) and antibody 8-OHdG (1:300) to each tissue, place the sections in a wet box, incubate overnight at 4°C, recover the primary antibody, and rinse the sections with PBS three times, 3 min each time. A negative control group with PBS added represents the primary antibody;
[0093] (6) Add 50 μl of fluorescent secondary antibody mixture to each tissue, place the sections in a light-proof humidified box, incubate at 37°C for 1 h, and rinse the sections three times with PBS, 3 min each time;
[0094] (7) Add 50 μl of anti-fluorescence quencher containing DAPI on each tissue, cover with a coverslip to avoid bubbles, and fix the coverslip with oily nail polish;
[0095] (8) Use an inverted fluorescence microscope to record and save images and perform statistical analysis.
[0096] 5. Detection of apoptosis level of hPDLSCs
[0097] 5.1 Experimental Grouping
[0098] (1) Blank control group (C): hPDLSCs were plated in a well plate and cultured for 24 h, then replaced with fresh DMEM complete medium and cultured for another 24 h;
[0099] (2) H2O2 group (H2O2): hPDLSCs were plated in well plates and cultured for 24 h, then the culture medium containing 0.75 mM H2O2 was replaced and cultured for another 24 h;
[0100] (3) 2-APB group (2-APB): hPDLSCs were plated in well plates and cultured for 24 h, and then the culture medium containing 25 mM 2-APB was replaced and cultured for another 24 h;
[0101] (4) 2-APB+H2O2 group: hPDLSCs were plated in well plates and cultured for 24 h. After 30 min, the complete medium containing 25 mM 2-APB was replaced, and then the complete medium containing 25 mM 2-APB and 0.75 mM H2O2 was replaced and cultured for another 24 h.
[0102] (5) NC-siRNA control group: hPDLSCs were plated in well plates and cultured for 24 h.
[0103] After 24 h, the cells were replaced with fresh DMEM complete medium and cultured for another 24 h;
[0104] (6) NC-siRNA+H2O2: hPDLSCs were plated in well plates and cultured for 24 h. The negative control NC was transfected into hPDLSCs for 24 h. The culture medium was replaced with complete medium containing 0.75 mM H2O2 and cultured for 24 h.
[0105] (7) siTRPM2 group: hPDLSCs were plated in well plates and cultured for 24 h, hPDLSCs were transfected with TRPM2 siRNA for 24 h, and then fresh DMEM complete medium was replaced and cultured for another 24 h;
[0106] (8) siTRPM2+H2O2 group: hPDLSCs were plated in well plates and cultured for 24 h, hPDLSCs were transfected with TRPM2 siRNA for 24 h, and then the medium containing 0.75 mM H2O2 was replaced and cultured for 24 h;
[0107] (9) The experiment was repeated three times, with three replicate wells in each group.
[0108] 5.2 MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide) assay for cell viability
[0109] (1) Prepare 5 mg / ml MTT solution: weigh 200 mg of MTT powder, add 40 ml of PBS solution, place the solution on a horizontal shaker, shake at 4°C to dissolve, filter through a 0.22 μl microporous filter, aliquot, store at -20°C in the dark, and take out and dissolve at 4°C before the experiment;
[0110] (2) hPDLSCs were digested with trypsin during the logarithmic growth phase and resuspended in fresh culture medium. 15 μl of the cell suspension was dropped into the small groove of the hemocytometer. After standing for 1 min, the cells were counted under an inverted microscope and the cell density was adjusted to 5×10 4 Pieces / ml;
[0111] (3) PBS was added to the outermost circle of the 96-well plate, and the cell suspension was inoculated into the 96-well plate at 100 μl / well, with 3 replicates per group;
[0112] (4) After the inoculation, the well plate was cultured in a 37°C, 5% CO2 incubator. After 24 hours, the medium was changed and drugs were added according to the experimental grouping conditions.
[0113] (5) After treatment with different concentrations of 0.75 mM H2O2 for 24 h, the supernatant was discarded, the serum-free medium was replaced, 20 μl of MTT was added to each well, and the cells were cultured in a 37°C, 5% CO2 incubator for 4 h;
[0114] (6) After the medium in the wells was discarded, 100 μl / well DMSO was added to the well plate and shaken on a horizontal shaker in the dark for 10 min. The OD value was detected by a microplate reader at a wavelength of 490 nm. Each group of experiments was repeated 3 times.
[0115] (7) Calculate cell activity according to the following formula:
[0116]
[0117] 5.3 TdT-mediated dUTP Nick-End Labeling (TUNEL) staining
[0118] (1) Preparation of cell slides: Add 1 drop of PBS in the center of a 24-well plate, place the 24-well slide in the center of the plate, digest hPDLSCs in the logarithmic growth phase with 0.25% trypsin to prepare a cell suspension, adjust the cell density to 4.2w / well and plate with 600 μl / well, let stand for 10 min, and then continue to culture in a 37°C, 5% CO2 incubator;
[0119] (2) Treat cells according to experimental grouping conditions;
[0120] (3) Rinse the cell slides with PBS three times for 3 min each time, fix with 4% paraformaldehyde at 4°C for 30 min, discard the fixative and rinse with PBS three times for 3 min each time;
[0121] (4) Prepare cell permeabilization solution according to Table 3, precool at 4°C, add 500 μl / well to the plate, permeabilize at 4°C for 20 min, and rinse with PBS three times, 5 min each time;
[0122] Table 3
[0123] Reagents capacity <![CDATA[ddH2O]]> 10ml Sodium Citrate 10mg TritonX-100 10μl
[0124] (5) Prepare a staining reaction solution with Label Solution and Enzyme Solution in a ratio of 9:1, add 50 μl of the reaction solution to each slide, incubate in a 37°C wet box in the dark for 1 h, and rinse with PBS 3 times, 5 min each time;
[0125] (6) Aspirate the excess liquid on the slide, seal the slide with an anti-fluorescence quencher containing DAPI, store it in the dark at 4°C for 6 h, and then take pictures with an inverted fluorescence microscope for statistical analysis.
[0126] 5.4 Flow cytometry
[0127] (1) hPDLSCs in the logarithmic growth phase were digested with 0.25% trypsin and resuspended, the cell density was adjusted to 24w / well, and the cells were seeded in a 6-well plate at a cell density of 2ml / well. After standing for 10 minutes, the plates were placed in a 37°C, 5% CO2 incubator for further culture;
[0128] (2) Treat cells according to experimental grouping conditions;
[0129] (3) Recover the old culture medium, rinse the cells once with sterile PBS, digest with 0.25% trypsin at room temperature for 2 min, neutralize the old culture medium and recover the cells, centrifuge at 1000 r / min for 5 min, wash and resuspend the cells with sterile PBS, and adjust the cell density to 10 6 pcs / sample, centrifuge at 1000r / min for 5min;
[0130] (4) After discarding the supernatant, add 195 μl of Annexin V-FITC binding solution to each tube. After mixing, add 5 μl of Annexin V-FITC and 10 μl of propidium iodide staining solution to each tube. Incubate at room temperature in the dark for 10 min before testing on the microscope.
[0131] 5.5 Western-blot detection of each protein
[0132] (1) hPDLSCs in the logarithmic growth phase were digested with 0.25% trypsin and resuspended, the cell density was adjusted to 3.6w / well, and the cells were seeded in a 6-well plate at a cell density of 600 μl / well. After standing for 10 minutes, the plates were placed in a 37°C, 5% CO2 incubator for further culture;
[0133] (2) Treat cells according to experimental grouping conditions;
[0134] (3) Sample preparation: When collecting samples, add an appropriate amount of SDS lysis buffer containing 1 mM PMSF, gently scrape the bottom wall after fully contacting the bottom of the plate, collect the lysed samples into 1.5 ml EP tubes, boil the samples at 100°C for 10 min, and store the samples at -20°C;
[0135] (4) SDS-PAGE gel electrophoresis
[0136] 1) Clean the 1.5mm glass plate and comb, dry them, fix the thick and thin glass plates, put them on the glue rack with sponge rubber strips as the bottom, and fix them again. Note that the thin plate is on the outside and the thick plate is on the inside, and ensure that the glass plate can move left and right on the glue rack.
[0137] 2) Gel preparation: Select the appropriate electrophoresis separation gel concentration according to the molecular weight of the target protein in the experiment. This experiment uses 10% separation gel and 5% concentration gel. The specific ratio is shown in Table 4 below:
[0138] Table 4
[0139] Add ingredients 10% separation gel (μl) 5% stacking gel (μl) Ultrapure water 3450 2000 30% Acrylamide 3050 500 1.5M TriL-HCL (pH 8.8) 2300 -- 1.0M TriL-HCL (pH 6.8) -- 375 10% SDS 90 30 10% APS 90 30 TEMED 3.6 3
[0140] 3) Glue filling: After the separation gel is prepared, quickly add it between the two glass plates until the liquid level reaches 3 / 4 of the height of the thin glass plate. Slowly and evenly fill the upper layer with ddH2O to fill the sealing liquid. Let it stand at room temperature for 20-30 minutes until a clear boundary appears between the separation gel and ddH2O. Pour off the upper layer of ddH2O and use filter paper to absorb the water. Be careful not to let the filter paper touch the separation gel. Add the prepared concentrated gel and quickly insert the comb to avoid the generation of bubbles. Let it stand at room temperature for 20-30 minutes until the concentrated gel is fully solidified.
[0141] 4) Sample loading: Install the electrophoresis device and inject the newly prepared electrophoresis solution, slowly pull out the comb to ensure that the concentrated gel between each loading well remains upright, and slowly add the prepared samples and markers to the loading wells;
[0142] 5) Electrophoresis: Check the direction of the electrodes and adjust the initial voltage to 80V. After about 45 minutes, the marker can be seen to be separated into layers in the separation gel. Then adjust the voltage to 120V. After about 100 minutes, bromophenol blue can be seen to the bottom of the separation gel, and the electrophoresis is terminated.
[0143] (5) Transfer
[0144] 1) Take out the gel glass plate, measure the length of the separation gel of the required molecular weight, cut out a PVDF membrane of corresponding length and width, mark it, and activate it in methanol for 30 seconds;
[0145] 2) Place the black transfer plate flat on its side in a tray filled with transfer solution, and then place the sponge and transfer filter paper in turn. Carefully cut the separation gel with a gel cutter and cover it on the transfer filter paper, then cover it with the PVDF membrane. Align the separation gel with the PVDF, and at the same time, remove the bubbles between the contact surface of the gel and the PVDF membrane. Then transfer the filter paper and sponge in turn, and fasten the transfer template after stacking them;
[0146] 3) Install the transfer tank equipment, confirm the electrode direction, add pre-cooled transfer solution, and place the transfer tank in an ice-water mixture. Adjust the setting parameters: constant current 300mA transfer for 90min.
[0147] (6) Closed
[0148] 1) Prepare blocking solution: Use 1×TBST solution to prepare 5% skim milk as blocking solution, and place the blocking solution on a horizontal shaker to fully dissolve the skim milk powder;
[0149] 2) Use tweezers to pick up the transferred bands, wash the bands with TBST, place them in blocking solution, and block them on a vertical shaker at room temperature for 60 minutes;
[0150] 3) Recover the blocking solution and wash the membrane three times with TBST, 5 min each time.
[0151] (7) Antibody incubation
[0152] 1) Prepare primary antibody: Use TBST to prepare primary antibody working solution (1:1000 TRPM2, 1:1000 Caspase3, 1:8000 β-actin). Use markers to locate and segment the bands where the target protein is located, place the bands in the corresponding primary antibody working solution, and incubate on a vertical shaker at 4°C overnight;
[0153] 2) Prepare secondary antibody: Goat anti-rabbit or goat anti-mouse at a ratio of 1:4000 using the recovered blocking solution and mix thoroughly on a horizontal shaker;
[0154] 3) Recover the primary antibody and wash the strips with TBST on a horizontal shaker three times, 5 min each time;
[0155] 4) Add the corresponding secondary antibody to each band and incubate at room temperature on a vertical shaker for 90 minutes;
[0156] 5) Discard the secondary antibody and wash the strips 3 times with TBST on a horizontal shaker, 5 min each time.
[0157] (8)ECL exposure detection
[0158] 1) Ultrasensitive chemical exposure solution: Mix solution A and solution B in a volume ratio of 1:1, protect from light and mix well for later use;
[0159] 2) Use filter paper to absorb the liquid on the strip, place the strip on the exposure plate, evenly apply exposure solution on the front of the strip, and incubate for 1 minute;
[0160] 3) After setting the exposure interval and exposure times, run the record and save the exposure images for subsequent analysis.
[0161] (9) Protein grayscale detection: After exporting the required bands, the grayscale value was determined by Image J software for statistical analysis.
[0162] VI. hPDLSCs osteogenic differentiation function test
[0163] (1) Experimental grouping: Same as 5.1
[0164] (2) Cell treatment
[0165] 1) hPDLSCs in the logarithmic growth phase were digested with 0.25% trypsin and resuspended, the cell density was adjusted to 3w / well, and the cells were seeded in a 24-well plate at a cell density of 600μl / well. After standing for 10 minutes, the plates were placed in a 37°C, 5% CO2 incubator for further culture;
[0166] 2) Treat cells according to experimental grouping conditions;
[0167] 3) ALP staining was performed after 7 days of induction in osteogenic differentiation medium, and ARS staining was performed after 21 days of induction.
[0168] (3) ALP staining
[0169] 1) After washing the cells with PBS, 4% paraformaldehyde was added to a 24-well plate at 500 μl / well and fixed at 4°C for 30 min. The cells were washed with PBS three times, 3 min each time;
[0170] 2) Prepare ALP staining working solution according to Table 3-1, add 200 μl / well to the well plate, incubate at 37°C in the dark for 30 min, and terminate color development with ddH2O;
[0171] 3) Allow to dry naturally, take photos using a stereo microscope, and save the images.
[0172] (4) ARS Alizarin Red Staining
[0173] 1) After inducing cell differentiation, remove the culture medium and wash once with PBS;
[0174] 2) Add fixative solution to the well plate at a volume of 300 μl / well, fix at room temperature for 20 min, and wash 3 times with PBS, 3 min each time;
[0175] 3) Add Alizarin Red S staining solution to the well plate at a volume of 300 μl / well, stain at room temperature for 15 min, terminate the reaction with ddH2O, wash thoroughly, dry naturally, and observe and photograph under a stereo microscope.
[0176] (5) Real-time PCR detection of osteogenesis-related factors
[0177] 1) RNA extraction, concentration and purity determination
[0178] a. hPDLSCs in the logarithmic growth phase were digested with 0.25% trypsin and resuspended, the cell density was adjusted to 18w / well, and the cells were seeded in a 6-well plate at a cell density of 2ml / well. After standing for 10 minutes, the plates were placed in a 37°C, 5% CO2 incubator for further culture;
[0179] b. Treat cells according to experimental grouping conditions and replace osteogenic differentiation medium for induction for 7 days;
[0180] c. Wash the cells twice with 4℃ pre-cooled PBS. After discarding the PBS, place the plate on ice and add 1ml of Trrizol Reagent to each well. Mix by pipetting to fully lyse the cells. Add the samples into 1.5ml RNA-free EP tubes according to the groups.
[0181] d. Add 200 μl of chloroform to each tube, shake repeatedly to mix evenly, let stand for 5 minutes, re-layer, and centrifuge at 12000 r / min at 4°C for 15 minutes;
[0182] e. Carefully transfer the upper layer of liquid after stratification to a new 1.5ml RNA-free EP tube, add an equal amount of isopropanol to each tube, shake well to mix, let stand for 10 minutes, centrifuge at 12000r / min at 4℃ for 10 minutes, and the white precipitate at the bottom of the tube after centrifugation is the precipitated RNA;
[0183] f. Add 1 ml of 75% ethanol prepared with DEPC water to each tube, centrifuge at 7500 r / min for 5 min at 4°C, discard the supernatant, and repeat twice;
[0184] g. Carefully suck out the remaining ethanol, and leave the tube open to dry in a clean bench;
[0185] h. Add appropriate amount of DEPC water according to the amount of RNA obtained in h, detect RNA concentration and purity using NanoDrop2000 ultra-micro spectrophotometer, adjust RNA concentration to 200-1000ng / ml, take 1μg RNA for reverse transcription, and store the rest at -80℃.
[0186] 2) Reverse transcription of RNA
[0187] a. Prepare 20 μl of reverse transcription system according to the ratio in Table 5 and operate on ice throughout the process;
[0188] Table 5
[0189] Reagents Volume (μl) 5xPrimseriptBuffer 4 PrimscriptRTEnzyme 1 OligodTPrimer (50μM) 1 Random6mers (100μM) 1 Total RNA Upto20 <![CDATA[RnaseFreedH2O]]> --
[0190] b. After thorough shaking, centrifuge and place the prepared reverse transcription system in a PCR amplification instrument. The reverse transcription program is: 37℃ for 15min, 85℃ for 5s. The cDNA obtained by reverse transcription can be transferred to the next step or stored at -20℃.
[0191] 3) Primer design
[0192] The osteogenesis-related gene primers RUNX2, ALP, COL1, OCN and the internal reference gene primer β-actin in this experiment were designed and synthesized by Wuhan Qingke Biotechnology Co., Ltd., as shown in Table 6.
[0193] 4) qRT-PCR
[0194] a. The obtained cDNA was prepared into a 20 μl reaction system according to Table 7, mixed in 8 tubes, and centrifuged to remove bubbles in the liquid;
[0195] b. After confirming the group, place the 8-tube strip in the StepOneTM real-time PCR amplification instrument and set the reaction program according to Table 8;
[0196] c. Set up 4 replicate wells for each group, and take the average value of each replicate well (Ct error between replicate wells < 0.15 is qualified). According to the Ct value results, the expression level of each mRNA relative to β-actin in each group of samples is obtained by the formula 2-ΔΔCt.
[0197] Table 6
[0198]
[0199] Table 7
[0200]
[0201] Table 8
[0202]
[0203] VII. Detection of mitochondrial reactive oxygen species in hPDLSCs
[0204] (1) Experimental grouping is the same as 5.1
[0205] (2) hPDLSCs in the logarithmic growth phase were digested with 0.25% trypsin and resuspended, the cell density was adjusted to 3w / well, and the cells were seeded in a 24-well plate at a cell density of 600 μl / well. After standing for 10 minutes, the plates were placed in a 37°C, 5% CO2 incubator for further culture;
[0206] (3) Treat cells according to experimental grouping conditions;
[0207] (4) After discarding the original culture medium, gently wash the cells twice with preheated PBS buffer;
[0208] (5) Add 200 μl of staining solution containing 300 nM Mitogreen and 500 nM MitoSOX prepared with PBS as solvent to each well and incubate at 37°C in the dark for 10 min;
[0209] (6) After discarding the staining solution, gently wash the cells with preheated PBS three times, and add 200 μl of preheated PBS containing 2% serum for the last time;
[0210] (7) Use an inverted fluorescence microscope to observe MitoSOX at an excitation wavelength of 543 nm and Mitogreen at an excitation wavelength of 488 nm. Take pictures to record the images and perform statistical analysis.
[0211] Experimental results:
[0212] Figure 1Figure 2 is a graph showing alveolar bone resorption in the experimental periodontitis model of TRPM2 knockout mice of the present invention. The results of stereomicroscopy showed that the distance from the cementoenamel junction to the alveolar ridge top (CEJ-ABC distance) of mice: compared with the WT group, the alveolar bone resorption in the WT+ligation group increased (P<0.05), which was consistent with the TRPM2 - / - Compared with the group, TRPM2 - / - +ligation group had an increased alveolar bone resorption (P<0.005) ( Figure 1 A), TRPM2 - / - +ligation group compared with WT+ligation group with decreased alveolar bone absorption (P<0.005) ( Figure 1 A, B). Micro-CT showed that the alveolar bone volume in the WT+ligation group was reduced compared with that in the WT group (P<0.005) ( Figure 1 A) and TRPM2 - / - Compared with the group, TRPM2 - / - +ligation group had a decrease in alveolar bone mass (P<0.005) ( Figure 1 A), TRPM2 - / - The alveolar bone resorption in the +ligation group was improved compared with that in the WT+ligation group (P<0.005) ( Figure 1 C); the periodontal bone density of the maxillary second molar was analyzed. The experimental results showed that compared with the WT group, the bone density of the periodontal tissue in the WT+ligation group was reduced (P<0.005), which was related to TRPM2 - / - Compared with the group, TRPM2 - / - +ligation group had decreased bone density in periodontal tissue (P<0.05), TRPM2 - / - The decrease in bone density of periodontal tissue in the +ligation group was improved compared with that in the WT+ligation group (P<0.05) ( Figure 1 D).
[0213] Figure 2 This is the TRAP staining diagram of the present invention. The test results show that the number of osteoclasts formed in the alveolar bone in the periodontitis group induced by silk thread ligation increased. At the same time, compared with the WT group, the number of osteoclasts formed in the WT+ligation group increased significantly (P<0.05), which was consistent with TRPM2 - / - Compared with the group, TRPM2 - / - +ligation group increased the number of osteoclasts (P<0.05), TRPM2 - / - The number of osteoclasts in the +ligation group was reduced compared with that in the WT+ligation group (P<0.05). Figure 2A, B). The experimental results showed that the number of osteoclasts in the periodontal tissue of mice with experimental periodontitis increased, and TRPM2 gene knockout could reduce the increase in the number of osteoclasts in the periodontal tissue of mice caused by experimental periodontitis.
[0214] Figure 3 The ALP staining diagram of the present invention is shown. The test results show that the osteogenic differentiation ability of the periodontal tissue in the silk thread ligation-induced periodontitis group is weakened. At the same time, compared with the WT group, the osteogenic differentiation ability of the periodontal tissue in the WT+ligation group is significantly weakened (P<0.005), which is consistent with TRPM2 - / - Compared with the group, TRPM2 - / - +ligation group had a weakened osteogenic differentiation ability of periodontal tissue (P<0.05), and TRPM2 - / - The osteogenic differentiation ability of periodontal tissue in the +ligation group was restored compared with that in the WT+ligation group (P<0.05) ( Figure 3 A, B). The experimental results showed that the osteogenic differentiation function of periodontal tissues in mice in the experimental periodontitis group was weakened, while the osteogenic differentiation function of mice was restored after TRPM2 gene knockout.
[0215] Figure 4 This is a test diagram of the immunofluorescence staining of the present invention to detect the expression of 8-OHdG in the periodontal tissue of mice. At the same time, TOM20 was used to mark mitochondria, and the fluorescence co-localization method was used to illustrate the level of mitochondrial oxidative stress. The results of immunofluorescence staining showed that the expression of 8-OHdG in the WT+ligation group was significantly increased compared with the WT group (P<0.05) ( Figure 4 A, B), TRPM2 - / - +ligation group and TRPM2 - / - Compared with the group, TRPM2 - / - +ligation group increased the expression of 8-OHdG in periodontal tissue (P<0.005), TRPM2 - / - The expression of 8-OHdG in periodontal tissues of the +ligation group was lower than that of WT+ligation (P<0.05). Figure 4 A, B). Therefore, knockout of the TRPM2 gene can reduce the level of oxidative stress in the periodontal tissues of mice.
[0216] Figure 5 The figure shows the changes in proliferation activity and apoptosis of hPDLSCs after adding TRPM2 inhibitor and TRPM2-siRNA in the present invention. The results of MTT experiment show that 2-APB( Figure 5 B) and siTRPM2( Figure 5 C) intervention can restore the proliferation activity of hPDLSCs after H2O2 stimulation. Figure 5HK), protein immunoblotting ( Figure 5 LQ) and TUNEL staining ( Figure 5 DG) The results showed that after 2-APB treatment, the rate of cell apoptosis was reduced compared with that under simple H2O2 stimulation.
[0217] Figure 6 The figure is a graph showing the changes in the osteogenic differentiation ability of hPDLSCs after adding TRPM2 inhibitors and TRPM2-siRNA in the present invention. The results show that the osteogenic differentiation ability of hPDLSCs was inhibited after H2O2 stimulation, while the osteogenic differentiation was partially restored after the intervention of 2-APB and siTRPM2 ( Figure 6 A, B). At the same time, the results of fluorescence quantitative PCR indicated that the expression of osteogenesis-related genes such as RUNX2, ALP, COL1, and OCN increased after the intervention of 2-APB and siTRPM2 ( Figure 6 CJ).
[0218] Figure 7 This is a diagram showing the changes in mitochondrial function of hPDLSCs after adding TRPM2 inhibitors and TRPM2-siRNA. Mitochondrial dysfunction is mainly manifested in abnormal mitochondrial ROS, abnormal membrane channels, and abnormal ATP production. The staining results showed that under H2O2 stimulation, mitochondrial ROS production increased significantly, and after 2-APB and siTRPM2 intervention, mitochondrial ROS production decreased ( Figure 7 AD). At the same time, under H2O2 stimulation, the mitochondrial membrane potential was significantly reduced, and after 2-APB and siTRPM2 intervention, the mitochondrial membrane potential was restored ( Figure 7 EH). Under H2O2 stimulation, the production of ATP decreased significantly, and after 2-APB and siTRPM2 intervention, ATP production increased ( Figure 7 I, J).
[0219] The present invention firstly constructed TRPM2 gene knockout mice by CRISPR / Cas9 technology, and constructed an experimental periodontitis model by ligating the maxillary second molars bilaterally with No. 5 ligature silk thread. It was found that TRPM2 gene knockout effectively alleviated periodontal tissue damage, which was manifested by reduced alveolar bone resorption level ( Figure 1 Shown), osteoclasts in periodontal tissue decreased ( Figure 2 The osteogenic differentiation function of alveolar bone was restored ( Figure 3 The oxidative stress level of periodontal tissues was reduced ( Figure 4 show).
[0220] Furthermore, by constructing an in vitro H2O2-induced oxidative stress injury model of human periodontal ligament cells (hPDLSCs), the role of TRPM2-mediated mitochondrial dysfunction in oxidative stress injury of periodontal ligament cells was double-verified using the TRPM2 chemical inhibitor 2-Aminoethyldiphenylbonnate (2-APB) and gene knockout, showing that the apoptosis level of hPDLSCs was reduced ( Figure 5 The osteogenic differentiation function of hPDLSCs was restored ( Figure 6 mitochondrial oxidative stress levels were reduced ( Figure 7 show).
[0221] In summary, the present invention has discovered a new use of TRPM2. The damage to periodontal ligament cells can be reduced by using a TRPM2 inhibitor, knocking out and / or knocking down the target TRPM2 gene, thereby effectively inhibiting the development of periodontitis. Based on the research on the role and mechanism of action of TRPM2 in periodontitis, it provides a new therapeutic target and new option for reducing oxidative stress damage to periodontal ligament cells in the treatment of periodontitis, and provides a target for developing products that reduce oxidative stress damage to periodontal ligament cells in the treatment of periodontitis. TRPM2 inhibitors can be used to prepare products that reduce oxidative stress damage to periodontal ligament cells in the treatment of periodontitis, and delivering TRPM2 inhibitors to periodontal ligament cells is a new option for the treatment of periodontitis.
[0222] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.
Claims
1. Application of a TRPM2-targeted prevention and treatment strategy in periodontitis, It is characterized in that TRPM2 is used as a drug target to screen products that reduce oxidative stress damage to periodontal ligament cells in the treatment of periodontitis.
2. The use of the prevention and treatment strategy targeting TRPM2 in periodontitis according to claim 1, It is characterized in that The product comprises an inhibitor of TRPM2.
3. The use of the prevention and treatment strategy targeting TRPM2 in periodontitis according to claim 2, It is characterized in that The TRPM2 inhibitor includes siRNA of the TRPM2 gene, RNA interference vector of the TRPM2 gene, antibody of TRPM2 or other inhibitors capable of inhibiting the expression of TRPM2.
4. Use of the prevention and treatment strategy targeting TRPM2 in periodontitis according to any one of claims 1 to 3, It is characterized in that The product includes a drug or a biologic.
5. Application of a TRPM2 inhibitor, It is characterized in that TRPM2 inhibitors are used to prepare products for reducing oxidative stress damage to periodontal ligament cells in the treatment of periodontitis.
6. A targeted drug for reducing oxidative stress damage in periodontal ligament cells in the treatment of periodontitis. It is characterized in that Contains an inhibitor of TRPM2.
7. The targeted drug according to claim 6, It is characterized in that The invention also comprises a pharmaceutically acceptable carrier, which is used for delivering the TRPM2 inhibitor to periodontal ligament cells in a targeted manner.
8. The targeted drug according to claim 6, It is characterized in that The TRPM2 inhibitor includes siRNA of the TRPM2 gene, RNA interference vector of the TRPM2 gene, antibody of TRPM2 or other inhibitors capable of inhibiting the expression of TRPM2.
Citation Information
Cited By
SiRNA of targeted PITX2 gene as well as medicine and application of siRNA
CN119570795A
